Search

Your search keyword '"Andreev, Dmitry N."' showing total 27 results
Start Over Author "Andreev, Dmitry N."
27 results on '"Andreev, Dmitry N."'

1. Evaluation of serum and urine biomarkers for severe COVID-19

Author

Shansky, Yaroslav D., primary, Yanushevich, Oleg O., additional, Gospodarik, Alina V., additional, Maev, Igor V., additional, Krikheli, Natella I., additional, Levchenko, Oleg V., additional, Zaborovsky, Andrew V., additional, Evdokimov, Vladimir V., additional, Solodov, Alexander A., additional, Bely, Petr A., additional, Andreev, Dmitry N., additional, Serkina, Anna N., additional, Esiev, Sulejman S., additional, Komarova, Anastacia V., additional, Sokolov, Philip S., additional, Fomenko, Aleksei K., additional, Devkota, Mikhail K., additional, Tsaregorodtsev, Sergei V., additional, and Bespyatykh, Julia A., additional

Published
2024
Full Text
View/download PDF

2. Microbial Signatures in COVID-19: Distinguishing Mild and Severe Disease via Gut Microbiota.

Author

Galeeva, Julia S., Fedorov, Dmitry E., Starikova, Elizaveta V., Manolov, Alexander I., Pavlenko, Alexander V., Selezneva, Oksana V., Klimina, Ksenia M., Veselovsky, Vladimir A., Morozov, Maxim D., Yanushevich, Oleg O., Krikheli, Natella I., Levchenko, Oleg V., Andreev, Dmitry N., Sokolov, Filipp S., Fomenko, Aleksey K., Devkota, Mikhail K., Andreev, Nikolai G., Zaborovskiy, Andrey V., Bely, Petr A., and Tsaregorodtsev, Sergei V.

Subjects
GUT microbiome, COVID-19, SARS-CoV-2, COVID-19 pandemic, ENTEROCOCCAL infections, HUMAN microbiota
Abstract

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global healthcare, underscoring the importance of exploring the virus's effects on infected individuals beyond treatments and vaccines. Notably, recent findings suggest that SARS-CoV-2 can infect the gut, thereby altering the gut microbiota. This study aimed to analyze the gut microbiota composition differences between COVID-19 patients experiencing mild and severe symptoms. We conducted 16S rRNA metagenomic sequencing on fecal samples from 49 mild and 43 severe COVID-19 cases upon hospital admission. Our analysis identified a differential abundance of specific bacterial species associated with the severity of the disease. Severely affected patients showed an association with Enterococcus faecium, Akkermansia muciniphila, and others, while milder cases were linked to Faecalibacterium prausnitzii, Alistipes putredinis, Blautia faecis, and additional species. Furthermore, a network analysis using SPIEC-EASI indicated keystone taxa and highlighted structural differences in bacterial connectivity, with a notable disruption in the severe group. Our study highlights the diverse impacts of SARS-CoV-2 on the gut microbiome among both mild and severe COVID-19 patients, showcasing a spectrum of microbial responses to the virus. Importantly, these findings align, to some extent, with observations from other studies on COVID-19 gut microbiomes, despite variations in methodologies. The findings from this study, based on retrospective data, establish a foundation for future prospective research to confirm the role of the gut microbiome as a predictive biomarker for the severity of COVID-19. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Development of a transcutaneous form of desloratadine.

Author

Ageev, Valentin P., Zaborovskiy, Andrey V., Yunina, Dina V., Tararina, Larisa A., Devkota, Mikhail K., Andreev, Dmitry N., Pyanzina, Aleksandra E., Shlyapkina, Vasilisa I., Buldygina, Yulia A., Kulikov, Oleg A., and Pyataev, Nikolay A.

Subjects
DESLORATADINE, DRUG development, SPECTROPHOTOMETRY, ALLERGIES, DRUG dosage
Abstract

Introduction: For people with allergies, it is not always possible to prevent allergens admission to the body. For this reason, it is essential to create a long-acting drug that can prevent an allergic reaction. The very promising option is a transdermal therapeutic system (TTS), with H1 blockers. The aim of the study: To create a technology for the production of desloratadine-based TTS, suitable for routine use with prolonged drug releasing. Material and Methods: Polyvinylpyrrolidone K30 (PVP) was used as the main matrix polymer for TTS, and the Kruofilm polymer membrane was used as the adhesive layer. The formation of the polymer membrane was carried out by drying a water-alcohol solution of the components at a temperature of 60ºC. Characterization of the obtained dosage forms was made by spectrophotometry. The resulting micelles size was measured by dynamic light scattering. Results and Discussion: Round shaped TTS (patches) with water-dissolved DL and its micellar form were obtained. The size of micelles with DL was 22.8±5.2 nm. The spectrophotometric method for determining DL has been developed. The containing of DL in the patches ranged from 5 to 25 mg per patch, depending on the manufacturing technology. Conclusion: We have developed TTSs containing DL by a solution and a micellar form. A top adhesive layer has been selected that has moisture resistance, strength and reliable fixation of the matrix with the active substance on the skin. A method for the spectrophotometric determination of DL in solutions and patches was developed and validated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Microbial Signatures in COVID-19: Distinguishing Mild and Severe Disease via Gut Microbiota

Author

Galeeva, Julia S., primary, Fedorov, Dmitry E., additional, Starikova, Elizaveta V., additional, Manolov, Alexander I., additional, Pavlenko, Alexander V., additional, Selezneva, Oksana V., additional, Klimina, Ksenia M., additional, Veselovsky, Vladimir A., additional, Morozov, Maxim D., additional, Yanushevich, Oleg O., additional, Krikheli, Natella I., additional, Levchenko, Oleg V., additional, Andreev, Dmitry N., additional, Sokolov, Filipp S., additional, Fomenko, Aleksey K., additional, Devkota, Mikhail K., additional, Andreev, Nikolai G., additional, Zaborovsky, Andrey V., additional, Bely, Petr A., additional, Tsaregorodtsev, Sergei V., additional, Evdokimov, Vladimir V., additional, Maev, Igor V., additional, Govorun, Vadim M., additional, and Ilina, Elena N., additional

Published
2023
Full Text
View/download PDF

7. Method of detection of dexamethasone in biological tissues and its application to assess the local kinetics of this drug

Author

Yunina, Dina V., primary, Ageev, Valentin P., additional, Zaborovskiy, Andrey V., additional, Tararina, Larisa A., additional, Tsaregorodtsev, Sergei V., additional, Kokorev, Alexander V., additional, Andreev, Dmitry N., additional, Pyanzina, Aleksandra E., additional, Shlyapkina, Vasilisa I., additional, Pyataev, Nikolay A., additional, and Kulikov, Oleg A., additional

Published
2023
Full Text
View/download PDF

14. Composition of oropharyngeal microbiota in patients with COVID-19 of different pneumonia severity

Author

Starikova, Elizaveta V., primary, Andreev, Dmitry N., additional, Galeeva, Julia S., additional, Sokolov, Philipp S., additional, Fedorov, Dmitry E., additional, Manolov, Aleksander I., additional, Pavlenko, Alexander V., additional, Klimina, Ksenia M., additional, Veselovsky, Vladimir A., additional, Zaborovsky, Andrew V., additional, Evdokimov, Vladimir V., additional, Andreev, Nikolai G., additional, Devkota, Mikhail K., additional, Fomenko, Aleksei K., additional, Khar'kovskii, Vadim A., additional, Asadulin, Pavel O., additional, Kucher, Sergey A., additional, Cheremushkina, Aleksandra S., additional, Yanushevich, Oleg O., additional, Maev, Igor V., additional, Krikheli, Natella I., additional, Levchenko, Oleg V., additional, Ilina, Elena N., additional, and Govorun, Vadim M., additional

Published
2022
Full Text
View/download PDF

26. Genome analysis of E. coli isolated from Crohn’s disease patients

Author

Rakitina, Daria V., primary, Manolov, Alexander I., additional, Kanygina, Alexandra V., additional, Garushyants, Sofya K., additional, Baikova, Julia P., additional, Alexeev, Dmitry G., additional, Ladygina, Valentina G., additional, Kostryukova, Elena S., additional, Larin, Andrei K., additional, Semashko, Tatiana A., additional, Karpova, Irina Y., additional, Babenko, Vladislav V., additional, Ismagilova, Ruzilya K., additional, Malanin, Sergei Y., additional, Gelfand, Mikhail S., additional, Ilina, Elena N., additional, Gorodnichev, Roman B., additional, Lisitsyna, Eugenia S., additional, Aleshkin, Gennady I., additional, Scherbakov, Petr L., additional, Khalif, Igor L., additional, Shapina, Marina V., additional, Maev, Igor V., additional, Andreev, Dmitry N., additional, and Govorun, Vadim M., additional

Published
2017
Full Text
View/download PDF

27. Nutritional Status in Patients with Chronic Pancreatitis

Author

Kucheryavyy, Yuriy A., Andreev, Dmitry N., Kucheryavyy, Yuriy A., and Andreev, Dmitry N.

Abstract

Chronic pancreatitis (CP) is defined as a continuing inflammatory disease of the pancreas that is characterized by irreversible morphological changes often associated with pain and the loss of exocrine and/or endocrine function, which may be clinically relevant. Maldigestion (absolute deficiency of pancreatic enzyme secretion) is a typical complication of CP of any etiology with long anamnesis. Fat malabsorption is considered to be the malnutrition base in CP patients. The purpose of this article is to evaluate the role of nutritive status and nutritive deficiency in CP patients, evaluate diagnostic approaches, correct nutritive status deviation with reference to previous experience, and explore the present situation and possible future perspectives.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results